Fibrosis - Pipeline Review, H2 2015
Summary
Global Markets Directs, ‘Fibrosis - Pipeline Review, H2 2015, provides an overview of the Fibrosiss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Fibrosis Overview 10
Therapeutics Development 11
Pipeline Products for Fibrosis - Overview 11
Pipeline Products for Fibrosis - Comparative Analysis 12
Fibrosis - Therapeutics under Development by Companies 13
Fibrosis - Therapeutics under Investigation by Universities/Institutes 15
Fibrosis - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Fibrosis - Products under Development by Companies 19
Fibrosis - Products under Investigation by Universities/Institutes 21
Fibrosis - Companies Involved in Therapeutics Development 22
Abeome Corporation 22
Acceleron Pharma, Inc. 23
Complexa, Inc. 24
Digna Biotech, S.L. 25
F. Hoffmann-La Roche Ltd. 26
FibroGen, Inc. 27
GlycoMimetics, Inc. 28
HanAll Biopharma Co., Ltd. 29
Isarna Therapeutics GmbH 30
Lycera Corp. 31
miRagen Therapeutics, Inc. 32
Neumedicines Inc. 33
Ribomic Inc. 34
RuiYi Inc. 35
Scholar Rock, Inc. 36
Siena Biotech S.p.A. 37
Silence Therapeutics Plc 38
SK Chemicals Co., Ltd. 39
UCB S.A. 40
XOMA Corporation 41
Fibrosis - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
ACE-2531 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Antibodies for Fibrosis - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Antibody to Inhibit Transglutaminase 2 for Fibrosis - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
disitertide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Drug to Activate Insulin Like Growth Factor for Fibrosis - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
G-XXX - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
HL-156FIB - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
IB-DMD - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ISTH-1047 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MGN-4220 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Monoclonal Antibodies to Inhibit IL-25 for Asthma, Fibrosis and Atopic Dermatitis - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NCE-401 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NMIL-121 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NPH-09 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
P-006 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PRI-724 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
RBM-003 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
RBM-007 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
RG-6069 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RNAi Oligonucleotide for Liver Diseases - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
RYI-028 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecule to Inhibit Galectin-3 for Fibrosis, Cancer and Cardiovascular Disease - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecule to Inhibit LOXL2 for Fibrosis - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecule to Inhibit MicroRNA for Vascular Fibrosis - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Inhibit Rho Kinase for Fibrosis - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecule to Inhibit Tankyrase/Wnt for Musculoskeletal, CNS and Oncology - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules for Inflammatory Diseases and Fibrosis - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules to Antagonize S1P3 for Inflammation, Neurodegenerative Diseases and Fibrosis - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules to Inhibit Procollagen C-Proteinase for Fibrosis - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecules to Inhibit SphK1 for Oncology, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Trophokine - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
XOMA-089 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Fibrosis - Recent Pipeline Updates 90
Fibrosis - Dormant Projects 95
Fibrosis - Dormant Projects 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 97
List Of Tables
List of Tables
Number of Products under Development for Fibrosis, H2 2015 11
Number of Products under Development for Fibrosis - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Comparative Analysis by Unknown Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Fibrosis - Pipeline by Abeome Corporation, H2 2015 22
Fibrosis - Pipeline by Acceleron Pharma, Inc., H2 2015 23
Fibrosis - Pipeline by Complexa, Inc., H2 2015 24
Fibrosis - Pipeline by Digna Biotech, S.L., H2 2015 25
Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 26
Fibrosis - Pipeline by FibroGen, Inc., H2 2015 27
Fibrosis - Pipeline by GlycoMimetics, Inc., H2 2015 28
Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 29
Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2015 30
Fibrosis - Pipeline by Lycera Corp., H2 2015 31
Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2015 32
Fibrosis - Pipeline by Neumedicines Inc., H2 2015 33
Fibrosis - Pipeline by Ribomic Inc., H2 2015 34
Fibrosis - Pipeline by RuiYi Inc., H2 2015 35
Fibrosis - Pipeline by Scholar Rock, Inc., H2 2015 36
Fibrosis - Pipeline by Siena Biotech S.p.A., H2 2015 37
Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2015 38
Fibrosis - Pipeline by SK Chemicals Co., Ltd., H2 2015 39
Fibrosis - Pipeline by UCB S.A., H2 2015 40
Fibrosis - Pipeline by XOMA Corporation, H2 2015 41
Assessment by Monotherapy Products, H2 2015 42
Number of Products by Stage and Target, H2 2015 44
Number of Products by Stage and Mechanism of Action, H2 2015 46
Number of Products by Stage and Route of Administration, H2 2015 48
Number of Products by Stage and Molecule Type, H2 2015 50
Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015 90
Fibrosis - Dormant Projects, H2 2015 95
List Of Figures
List of Figures
Number of Products under Development for Fibrosis, H2 2015 11
Number of Products under Development for Fibrosis - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 42
Number of Products by Top 10 Targets, H2 2015 43
Number of Products by Stage and Top 10 Targets, H2 2015 43
Number of Products by Top 10 Mechanism of Actions, H2 2015 45
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 45
Number of Products by Routes of Administration, H2 2015 47
Number of Products by Stage and Routes of Administration, H2 2015 47
Number of Products by Top 10 Molecule Types, H2 2015 49
Number of Products by Stage and Top 10 Molecule Types, H2 2015 49
